Aptinyx Inc - APTX stock
Description[edit]
Aptinyx Inc. is a biopharmaceutical company in the clinical stage, specializing in the discovery, development, and commercialization of unique, proprietary, and synthetic small molecules designed to address brain and nervous system disorders. Their primary product candidate, NYX-783, is an N-methyl-D-aspartate receptors (NMDAr) modulator undergoing Phase I clinical trials for opioid use disorder (OUD) treatment and preclinical trials for alcohol use disorder (AUD) treatment. The company is based in Evanston, Illinois, and also maintains a research collaboration agreement with Allergan plc.[1]
History[edit]
Aptinyx Inc. was founded in 2015 as a clinical-stage biopharmaceutical company. The company's origin can be traced back to the collaboration of a team of scientists and researchers with expertise in neuroscience and drug discovery. The founders of Aptinyx recognized the significant unmet medical needs in the area of brain and nervous system disorders, which can be highly debilitating and impact millions of people worldwide. They aimed to develop novel and proprietary small molecule drugs that could address these conditions more effectively.[2]
Drawing on their expertise and insights into the biology of brain disorders, the team identified the N-methyl-D-aspartate receptors (NMDAr) as a promising target for drug development. NMDA receptors play a crucial role in brain function and have been implicated in various neurological and psychiatric disorders.[3]
With a focus on the discovery, development, and commercialization of innovative treatments, Aptinyx likely secured funding and strategic collaborations to advance their research and pipeline of small molecule drugs. One of their lead product candidates, NYX-783, was designed as an NMDAr modulator and targeted for clinical trials in conditions like opioid use disorder (OUD) and alcohol use disorder (AUD).[4]
As a clinical-stage company, Aptinyx's early years involved conducting preclinical research, optimizing drug candidates, and navigating the necessary regulatory processes to initiate clinical trials. The collaboration agreement with Allergan plc likely provided additional resources and expertise to support their research and development efforts. Since its founding, Aptinyx has continued to advance its drug candidates through various stages of clinical development and has likely expanded its portfolio of potential treatments for brain and nervous system disorders.
Trial Results
In February, 2023, the company announced results of Phase 2 clinical trials for NYX-458 in patients with Parkinson’s disease and dementia. According to the company, "Across the overall study population, NYX-458 did not demonstrate clinically meaningful improvements over placebo on the study’s efficacy endpoints. The results do not support further development of NYX-458 by the company."[5]
Dissolution[edit]
On June 30, 2023, stockholders approved the dissolution and liquidation of the company.[6] Under the Plan of Liquidation and Dissolution filed with the SEC, the company will pay all obligations and distribute any remaining funds to stockholders.[7]
- ↑ Yahoo Finance. APTX Stock Profile. Retrieved on 7/29/2023.
- ↑ aptinyx.com. Aptinyx Debut Press Release. September 16, 2015.
- ↑ National Institute of Health. NYX‐2925, A Novel N‐methyl‐D‐aspartate Receptor Modulator: A First‐in‐Human, Randomized, Double‐blind Study of Safety and Pharmacokinetics in Adults. September 29, 2018.
- ↑ BioSpace. Aptinyx Initiates Phase 2b Study of NYX-783 in Patients with Post-Traumatic Stress Disorder. December 16, 2021.
- ↑ Yahoo Finance. Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update. February 27, 2023.
- ↑ aptinyx.com. Home. Retrieved on 8/3/2023.
- ↑ sec.gov. Plan of Liquidation and Dissolution. Retrieved on 8/3/2023.
